Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors

Trial Profile

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Lurbinectedin (Primary) ; Doxorubicin
  • Indications Adenocarcinoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 06 Jun 2017 Results of this and other trials (n=97) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 19 May 2017 According to a PharmaMar media release, data from this trial will be presented at the 53rd Congress of the American Society of Clinical Oncology (ASCO) 2017.
    • 10 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top